一家生物科技公司报告称, 实验性肥胖药物导致体重减轻与销量最好的治疗方法相似. A biotech firm reports its experimental obesity drug caused weight loss similar to top-selling treatments.

美国旧金山南部的一家生物技术公司 Structure 在实验中发现其肥胖药物有望减轻体重, 与诺沃北方和伊利莉的治疗方法相比. A South San-Francisco biotech company, Structure, has reported promising results from its experimental obesity drug, showing weight loss comparable to leading treatments from Novo Nordisk and Eli Lilly. 根据早期临床试验的结果, 这种药丸可以在不断增长的减肥药品市场中提供竞争力更强的替代方案. The findings, based on early clinical trials, suggest the pill could offer a competitive alternative in the growing market for weight-management medications. 公司计划将药物推向后期测试, 可能需要几年才能获得批准. The company plans to advance the drug into later-stage testing, with potential approval years away.